The QualityStocks Daily Blog
Covering Micro-Cap and Small-Cap Companies

Solar Wind Energy Tower is an ingenious little company with some key patent applications on their tech, including an improved wind energy power transmission system using multi-stage variable hydraulic drives that can achieve high efficiencies across a wide range of speeds, and an energy tower having external wind capturing capacity that dovetails exceptionally well with their flagship Solar Wind Downdraft Tower concept.

Effectively, this is a solar/wind concept which can also be constructed with large, vertical vanes that help to capture additional prevailing winds, but which primarily operates on very simple downdraft physics. Basically you have a huge hollow cylinder structure with wind tunnels at the base that have turbines in them. The design functions exceptionally well in hot environments and represents a large-scale passive capture strategy using water which is misted out across the opening and evaporates in the hot, dry air, forcing the outside warmer air to downdraft through the cylinder at speeds in excess of 50mph.

The Solar Wind Energy Tower is remarkably efficient, generating electricity at a cost per kilowatt similar to typical coal or gas-fired plants. The company moved to further improve this efficiency back in April, partnering strategically with Commonwealth Dynamics, who have developed (in conjunction with the Whiting Turner Contracting Company) an adaptation of a hyperbolic, thin-walled concrete structure. This key breakthrough in the Solar Wind Energy Tower’s design offers multiple advantages, from drastically reduced cost, complexity, and time for the building of the structure, to elimination of onsite assembly/fabrication requirements when using steel. The company’s goal has always been to offer the most cost effective and efficient clean energy system available, confident that to truly be successful, an alternative energy producer must be able to survive and thrive without subsidies.

President and CEO of SWET, Ronald Pickett, a 40-year veteran in the construction, development, and technology arena, who has nurtured three highly-innovative startups from inception through to public ownership, noted that steel was still a valid design choice in regions that called for even taller structures to be built, but that this new thin-walled hyperbolic concrete implementation was ideal for the towers. While they certainly won’t be ruling it out, the price/performance metrics on the new Commonwealth Dynamics implementation has already made it the de facto standard in tower design for SWET.

Utilizing new software which can calculate and predict energy production for a Solar Wind Downdraft Tower based on empirical, local weather data, SWET has managed to shave a whopping 750 feet off the basic tower height (down to 2,250 in the specs). This software allows for dynamically configuring tower height/diameter before building, as well as the amount of water appropriate to be used as fuel. We are talking roughly 500 megawatt hours net (1.25k gross potential at maximum capacity) on the specs for the first San Luis Tower at just 60% capacity (435 Mwh average across an entire year when factoring in the winter season). This global energy generation calculator software is indispensible as an analytical tool moving forward for SWET and represents a year or more of development time by the company, as well as the ideal means of positioning the Solar Wind Downdraft Tower concept before global markets. SWET can go to an interested party with accurate specs and potential output data with data-driven analytics to show the client, making commercialization, especially in the EU and other green energy hungry markets, an easy sell.

Selling clean energy to the grid also opens up the carbon credit angle and SWET has wasted no time moving to take advantage of this strategic play, scoping out the potential of a planned project in Mexico to produce international, highly-marketable carbon credits, as well as the aforementioned location in San Luis, Arizona, which should generate some $250M in investment tax credits (based on IRS guideline projections). The cachet value alone in global markets for the design, when fully commercialized, is profound enough to grab the market’s attention and SWET is well aware of this fact. They have a robust, highly passive, and extremely efficient green energy production model on their hands here and are looking to push the envelope in hybridized wind/solar generation technology.

The running idea of building large compounds, consisting of many such towers, deployed in optimal locales and design-scaled using the company’s software to further tweak the yields, introduces even greater efficiency into this model, as associated construction, labor, water sourcing, and the like can be localized/streamlined. It is almost like sinking wells in a grid pattern to optimize hydrocarbon extraction on a piece of given acreage, only here we are building up, sky-drilling for premium thermal vectors and creating the downdraft towers. The most efficient turbines at the base, the new thin-walled hyperbolic concrete for the structure, and highly efficient water distribution systems all combine in this tower design, taking full advantage of the underlying physics in a truly ingenious way.

For more info visit www.CleanWindEnergyTower.com

Let us hear your thoughts below:

Leading provider of Personal Health Records, MMRGlobal has announced two new additions to its Medical Board of Advisors. New York Times best-selling author on children’s health and parenting, Dr. Cara Natterson, M.D., is to join as well as Concierge Medicine Specialist Dr. Jeremy Fine, M.D.

A Board-Certified Pediatrician, Dr. Natterson will assist MMRGlobal with its goals to educate parents on the medical importance and relevance of having Personal Health Records for their children. She will help advocate the best ways to offer Personal Health Record products and services through pediatricians. Board-Certified in Internal Medicine, Dr. Fine will oversee MMRGlobal’s education of Concierge Medicine professionals. He will also ensure patients maintain a current Personal Health Record.

The official announcement of MMRGlobal’s newest additions was made during CEO Bob Lorschs appearance on a Fox News Radio show, during his 30-minute interview on “The Vipp Jaswal Report.” During the interview Lorsch discusses MMR’s business model as well as humanitarian efforts regarding the release of Dr. Shakil Afridi.

A five-time author, Dr. Natterson inked “Worry Proof,” which was awarded The Wall Street Journal’s Best Health Book of the Year Award. She also penned the American Girl book, “The Care & Keeping of You 2.” Additionally she updated American Girl’s original “The Care & Keeping of You,” which has sold about three million copies. A former Clinical professor of Medicine at both UCLA and USC Schools of Medicine, Dr. Natterson was named by Los Angeles Magazine as one of the Best Doctors in Los Angeles, CA.

Dr. Natterson currently consults for a number of Fortune 500 companies in need of expert consultation on child wellness, health, and safety issues. Her company Worry Proof Consulting is the first pediatric practice of its kind, offering parents open-ended time to review everything from medical questions to parenting issues.

“Dr. Natterson and Dr. Fine will make a great addition to the Company’s Medical Board of Advisors, helping us educate two specialty markets on the value of PHRs,” commented Lorsch. “Dr. Natterson’s role is to strategically introduce MyMedicalRecords to the pediatric market in an effort to make both pediatricians and parents aware of the importance of having a PHR for children at a very young age. Dr. Jeremy Fine truly exemplifies what Concierge Medicine is all about and being there for his patients whenever and wherever they need him.”

Dr. Fine has routinely and skillfully deployed MyMedicalRecords accounts over the past several years to many of his Concierge Medicine patients as part of his Concierge Medicine policy and protocol. “As a result, Dr. Fine knows first-hand how valuable it can be in an emergency at 2 a.m. to have the ability to log in to MyMedicalRecords and access a patient’s critical information regardless of where he or his patients are in the world. Consumer awareness of the importance of having a PHR is critical to the Company’s business plan and there are no better professionals than Drs. Natterson and Fine to carry our message to physician colleagues, patients and parents,” added Lorsch.

Additionally Dr. Fine has served on the Medical Informatics Committee at Cedars-Sinai Medical Center, Executive Committee and the Bioethics Committee. He is a graduate of Harvard College and Johns Hopkins School of Medicine, trained in pediatrics at the University of California at San Francisco. He was also chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles and was named as one of California’s Favorite Physicians.

A company founded on working with highly qualified healthcare professionals and medical advisers, including the company’s own, MMRGlobal continues to focus on its Personal Health Record services and licensing. The company currently generates revenue from the sale of Personal Health Records to employers for employee benefits. Through MMRGlobal’s wholly owned operating subsidiary MyMedicalRecords, patients are provided a secure online Personal Health Record which then enables them and their families to access medical records and other valuable documents like birth certificates online at anytime.

To learn more about MMRGlobal, visit www.mmrglobal.com

Let us hear your thoughts below:

Terra Tech Corp., a leader in sustainable hydroponic produce cultivation, recently announced revenue guidance of $800,000 for the second quarter 2013.

Sales through Edible Garden and its line of locally grown hydroponic produce, which is distributed throughout the Northeast, have been strong for Terra Tech since the close of the merger in April. To date the company has recognized sales of approximately $200,000 in the second quarter, which is an increase of 300% compared to Q2 2012.

“Management is pleased to announce its anticipated strong revenue growth for the company’s second quarter 2013,” stated Derek Peterson, CEO of Terra Tech. “We expect Q2 2013 to be a record quarter for Terra Tech primarily due to the successful integration of Edible Garden. We believe that we are well positioned throughout the Northeast and forecast our revenue growth will come from our line of Living Produce. The company is dedicated to its strategy of securing new contracts, entering new markets through partnerships, and improving shareholder value.

Edible Garden’s living produce is hydroponically cultivated and delivered to stores with its root system intact. The produce is never cut or truly harvested resulting in a live product that continues to grow ensuring consumers the freshest and most nutritious produce available. Their products are available in approximately 400 retailers throughout New Jersey, Connecticut, Delaware, Maryland, New York and Pennsylvania.

For more information about Terra Tech Corp visit: www.terratechcorp.com

Let us hear your thoughts below:

SmallCapVoice.com, Inc. announced today that a new audio interview with Marley Coffee, an artisan roasted gourmet coffee, is now available. The interview can be heard at http://smallcapvoice.com/blog/5-15-13-smallcapvoice-interview-with-marley-coffee-jamn.

Brent Toevs, CEO, Marley Coffee, called into SmallCapVoice.com to go over the annual report for the year ended 1/31/2013. The interview includes discussion on the sales growth, expansion in the international markets, the steady growth in the Real Cup market, and several other key points.

For more information on Marley Coffee, or for general sales inquiries, visit www.marleycoffee.com.

Let us hear your thoughts below:

P2 Solar was pleased to report today that they have successfully completed the full acquisition of their first renewable energy project in India via newly formed and wholly-owned subsidiary, Jagat Energy Private Limited, a choice little 700 KW mini-hydro job on a Sidhwan irrigation canal diversion in Ludhiana (Punjab). Known as the Rajgar mini-hydro site, this newly acquired project is fully permitted, as well as construction-ready, and will initially consist of a small turbine installation and the associated hardware.

Given the nature of the target waterway and planned implementation, this is an ideal project for PTOS, with virtually no impact on the main water channel or surrounding terrain. Moreover the company will be using a time-tested, proven hydro power model that has achieved environmentally sustainable energy production the world over. The company has even slated a potential PV Solar array for the open area above the several kilometers of canal space they have acquired rights to and there looks to be plenty of room here for significant, phased expansion.

Punjab is a thriving region with massive demand from a growing consumer base, and it is riddled with thousands of kilometers of canals that can be viewed by investors as a rich target market for PTOS. The company is set to go into construction on the Rajgar mini-hydro site as early as this summer and revenue projections are already looking cherry, with $443k/yr from the hydro and some $2.95M/yr from the proposed 10 MW solar array. While capital intensity on such projects can be daunting, the superb management team at PTOS has shaved the edges off their implementation model and they are supremely confident that the fusion of rigorous oversight and low facility operating cost is a good recipe for healthy cash flows (EBITDA margin estimates of 95% for the mini-hydro and 93% for the solar).

CEO of PTOS, Raj-Mohinder Gurm, emphasized the receptivity of local and national officials to this sort of project, which will help free India’s crippling dependence on increasingly cost-prohibitive hydrocarbons like imported coal. The local Punjab government is keen to utilize their canal networks like this and PTOS shareholders are poised to reap the rich rewards while helping to bring a good model to India that incorporates PV Solar arrays on the areas above the canals. This is much-needed electricity in a nation where demand is growing at annual rate of 10%. With the electric bills for some consumers across India seeing jumps of 10% to 20% per year and improving renewable price metrics, Gurm sees this acquisition as a major milestone for PTOS and a serious foothold in India’s rapidly expanding, $20B plus annually, clean energy sector.

This little beauty should make envious neighbors of surrounding states, pumping out hundreds of megawatts to consumers in Punjab and the potential for such mini-hydro implementations should become abundantly clear in short order, especially when you throw in that solar component that would use what is generally completely unused space above the canals. This is an exceptionally attractive component architecture model that PTOS has put together and the company is already chomping at the bit to secure additional market share in target-rich India on the back of this concept.

For the latest news and info on P2 Solar, visit www.P2Solar.com

Let us hear your thoughts below:

GNCC Capital holds six different gold and silver exploration properties in Arizona that the company plans to develop through the use of exploration, testing, and joint ventures.

Current gold properties:

• Burnt Well Gold Properties
• Ester Basin Gold Properties
• Clara Gold Properties

Current silver properties:

• Kit Carson Silver Properties
• Potts Mountain Silver Properties
• Silverfields Silver Properties

The company sees itself as having a number of strengths that will help drive its strategy as it continues to acquire and develop properties.

• The company has world-class management, with decades of experience in finance and mining.

• The company continues to identify sound acquisitions to increase the size of its mining portfolio.

• The company is current in its filings with the OTC Markets Group, and is labeled as “CURRENT INFORMATION.”

• The availability of historic data on the tenements owned by the company should allow a higher than normal return.

• The company’s existing and initial portfolio of six gold and silver mining properties were very carefully selected due to their outstanding characteristics as exploration properties, coupled with management’s belief that it can rapidly and inexpensively drill out a “Resource Base.”

• The company’s directors hold 12% of the outstanding shares of common stock, aligning their interest with those of the stockholders.

• There is a fairly small “Float” of free-trading unrestricted shares of common stock.

• Company shares are DTC Eligible.

• Company management is committed to not increasing the number of shares of outstanding common stock.

• The company’s management would consider a dual listing of its shares of common stock on the Frankfurt Exchange in Germany, which would open the company to European markets and investors.

For more information, visit www.GNCC-Capital.com

Let us hear your thoughts: GNCC Capital, Inc. Message Board

Liberator Medical Holdings reported its financial results for the second fiscal quarter and six months ended March 31, 2013, reflecting revenue and earnings growth for both periods.

Sales for second quarter of 2013 increased 14.1 percent to $16.7 million, as compared with sales of $14.6 million for the same three months of 2012. Sales for the six months ended March 31, 2013, increased by 16.4 percent to $34.2 million, as compared with sales of $29.4 million for the six months ended March 31, 2012.

Net income was $1.4 million, or $0.03 diluted earnings per share, compared with net income of $0.7 million, or $0.01 per share, for the second quarter last year. For the first six months of 2013, net income was $2.7 million, or $0.05 per share, compared to $1.1 million, or $0.02 per share, reported for the first six months of 2012.

Second-quarter income from operations increased 107.2 percent to $2.3 million, as compared to $1.1 million in the prior year period. For the first six months of 2013, income from operations increased to $4.6 million, as compared to $1.9 million in the first six months of 2012.

Net income for the second quarter of 2013 increased 112 percent to $1.4 million, as compared to $670,000 for the comparable three months of 2012. Net income for the six-month period increased 147 percent to $2.7 million, as compared to $1.1 million for the comparable six months ended March 31, 2012.

As of March 31, 2013, Liberty Medical had $7.0 million of cash and $4.3 million available from its credit line facility.

“We continue to manage the level of our direct response advertising spend to maximize profitability and cash flows for fiscal year 2013. During the first half of fiscal year 2013, we increased our sales by 16 percent, improved our operating margins to 13.4 percent of sales, and generated $4.1 million in operating cash flows for the first six months of fiscal year 2013 compared with the first six months of fiscal year 2012,” Mark Libratore, Liberator Medical’s president and CEO, stated in the press release. “We expect to continue to increase our operating margins and cash flows during the second half of fiscal year 2013 compared with fiscal year 2012.”

On April 3, 2013, the company’s board of directors approved a cash dividend of $0.02 per common share to its shareholders.

For more information, visit www.liberatormedical.com

Let us hear your thoughts below:

On May 16, eFuture Information Technology announced that it would be providing SCA China Holding Co. with cloud services, in the form of its Data Link products. eFuture’s cloud services launched in May of 2012, and is available with no added hardware via a monthly subscription fee.

eFuture is focused on providing software and services to China’s retail and consumer goods industries, as well as providing software and services to manufacturers, distributors, wholesalers, logistics companies, and retailers in China’s front-end supply chain market.

The company’s products include Salesforce Automation, a sales management application allowing manufacturers and their distributors to manage sales force efficiency. Data Link products, such as the products specified in the SCA agreement, are distributor relationship management applications that allow manufacturers and distributors to access supply chain data.

eFuture’s Data Link services will allow SCA to access real-time sales, inventory, and replenishment information directly from their distributors.

For more information, visit www.e-future.com.cn

Let us hear your thoughts below:

Leading technology and management consulting company Dynamics Research Corp. (DRC) has announced that the Department of Veterans Affairs (VA), through the General Services Administration, has exercised the third year option of the Veterans Relationship Management Portfolio Monitoring and Coordination contract, extending the period of performance until May 10, 2014. The contract was awarded in May 2010 to High Performance Technologies, Inc., the company’s wholly owned subsidiary, and has a five-year performance period through May 2015 and a total contract value of $125.5 million.

A multi-year initiative, Veterans Relationship Management restarts previously troubled programs with the end goal of providing veterans, service members, and eligible beneficiaries with fast, accurate, and easily accessible healthcare information and benefits. DRC delivers the next generation of IT solutions geared for veterans, providing a full range of program and portfolio management services across more than 30 projects. The company’s solutions include identity management, advanced voice-recognition tools, enhanced Web self-services tools, and integrated desktop interfaces.

DRC is engaged in providing program architecture, program planning and management, requirements analysis, IV&V, and life cycle engineering to create an IT system that provides veterans with access to the VA through various methods, enables them to access information about VA benefits and services through a uniform interface, and allows them to complete multiple business processes within the VA without the necessity of reentering identifying information.

For more information, visit www.drc.com

Let us hear your thoughts below:

Yesterday, Aspen Group, a nationally accredited online postsecondary education company, announced that Michael Matte has been named as the company’s Chief Financial Officer, effective immediately.

Matte is taking over this role form David Garrity, Aspen’s former CFO; Garrity has been appointed EVP, Corporate Development, where he will head Aspen’s investor relations activities, M&A, and corporate partnerships. He will also be responsible for building Aspen’s corporate sales function, which is focused on institutional partnerships.

Matte is joining Aspen Group having most recently been at MeetMe, Inc. as its CFO. He has over 20 years of experience as a CFO of both technology and public companies. A Certified Public Accountant in Florida, Matte began his career in public accounting with Price Waterhouse. He holds a Bachelors of Science from Florida State University,

Michael Mathews, Aspen’s Chairman and CEO, remarked, “We are delighted to have attracted Mike to join the Aspen team and we welcome him. He is a strong financial and operational executive with outstanding leadership experience. His track record of managing businesses and positioning them for sustainable, profitable growth is impressive and I look forward to working with him as we continue to identify opportunities to increase shareholder value at Aspen.”

For more information, visit www.aspen.edu

Let us hear your thoughts below:

Mobile devices have become an indispensable personalized link to the outside world in ways that the developers of the original location-locked telephone never could have imagined. Increasingly we take our world with us, demanding answers and reach wherever we are, at any time of the day or night. It’s a tall order when you consider the volume and complexity of every person’s unique information flow.

Over half of online activity now occurs through mobile devices, especially impressive when you consider the fact that Google alone, a focal point for online activity, gets over a billion visits every day. It translates into billions of mobile devices serving the human global population, and a market of staggering size and scope led by Samsung, Nokia, and Apple.

Although every new iteration of mobile device brings with it new capabilities and perceptions, which can cause swings in the mobile marketplace, the companies that provide accessories to such devices are in a smart position. Changes in devices are often internal, leaving associated accessories still applicable. Even if the changes affect accessory use, it simply represents a new opportunity for accessory producers to modify their product and sell to a new market.

DoMark International, through its subsidiary SolaWerks, is aggressively tapping the mobile device accessory market, with technology-based products that fit an important need and are differentiated in the marketplace. In particular, the company’s new IR Charger Case, with innovative patent pending INFRASOL technology that provides both infrared and solar charging features for Apple iPhone and Samsung Galaxy devices, is also backed up with two high density lithium batteries providing an additional doubling of battery life.

The scheduled launch for the new product is in August of this year, and is aimed at the millions of Apple iPhone and Samsung product users around the world. DoMark CEO, Andy Ritchie, stated, “There is nothing in the market like this product, and we wanted to make sure we were completely ready to handle a large global role out and huge demand.”

For more information, visit www.DoMarkIntl.com

Let us hear your thoughts: DoMark International, Inc. Message Board

A global provider of advanced communications and mobile broadband services, iTalk has announced the appointment of Clive Raines as Director of Australasia and Europe Operations. With high voice quality and the lowest prices, iTalk Mobile is currently pushing the market for an industry alternative to traditional cellular coverage. Raines, whose resume includes extensive experience in better business practices in Australasia and Europe, will be welcomed to the team for his strong background in sales, marketing, strategic product development, and distribution.

David F. Levy, Chief Executive Officer of iTalk, commented, “The Australasia and Europe region is poised for the same explosive growth in new communication devices and services that iTalk is currently offering to the US marketplace.” Continuing on Levy stated, “Clive is an excellent addition to our growing team and his 25 years of international communications, product development and distribution experience in Australasia and European countries, will allow iTalk to utilize his unique skills and knowledge to expand our global footprint and make our products the most competitive in the region.”

With extensive international experience establishing and developing next generation telecom companies for IP based services, Raines brings a strong background of management. The man’s resume includes senior management roles, management consulting, marketing, international project management, technical project management, CRM, as well as business development.
Raines previously sat as President of International Operations for TheGlobe.com, a VoIP provider and currently one of the most successful dot-com IPOs in NASDAQ’s long history. With an impressive resume in telecommunications, Raines has received extensive technical management, certifications, and product training with numerous international technology and telecommunications companies.

A mobile communications company, iTalk uses innovative technologies to offer consumers a high quality cellular alternative while severely undercutting all major national carriers. Through iTalks’ extensive network, consumers will have access to offers that include nationwide voice and data coverage to about 280 million people in over 12,900 cities.

To learn more, visit www.italkmobility.com

Let us hear your thoughts below:

Rafarma Pharmaceuticals is one of Russia’s newest and most promising pharmaceutical companies. A company whose development and growth is being actively encouraged by the government, in a move to lessen Russian dependence upon western pharmaceutical companies for widely used pharmaceuticals, Rafarma is currently specializing in the production of generic antibiotics, but has a growing pipeline of other drugs, including proprietary products already approved.

The company expects significant near-term results with its line of current and researched pharmaceuticals, including the following group of antibiotics.

• Benzalconium Fluoride – Open randomized study of the efficacy and safety of the drug “benzalkonium fluoride, topical solution 1 %” in patients with purulent-infected wounds.
• Benzomet – Open randomized study of the efficacy and safety of the drug “benzomet, vaginal suppositories” in patients with urogenital trichomoniasis.
• Benzolete – Open randomized study of the efficacy and safety of “benzolete, lozenges for resorption – 1 mg” in patients with inflammatory diseases of the mucous membranes of the oral cavity and pharynx.
• Benzoteks – Open randomized study comparative study of the efficacy and safety of the drug “benzoteks, vaginal suppositories with benzalkonium FLUORIDE – 18.9 mg” in patients with bacterial vaginosis.

Below is a list of various Rafarma products, in order of expected sales (USD) by 2014. Rafarma also deals with many drugs for contracted production.

• Pasco ($5,910,186)
• Amoxicillin+clav-k ($5,700,175)
• Azithromycin ($4,782,939)
• Clopidogrel ($4,088,210)
• Betahistine ($3,795,417)
• Glibenclamide+Metformin ($3,463,513)
• Metoprolol ($2,911,183)
• Metformin ($2,865,075)
• Bisoprolol ($2,418,957)
• Levofloxacin ($2,338,084)
• Glycine ($2,274,287)
• Vancomycin ($1,467,387)
• Quetiapine ($1,354,435)
• Cefotaxime ($1,193,041)
• Clarithromycin ($1,015,775)
• Ciprofloxacin ($839,219)
• Ibuprofen ($749,831)
• Glimepiride ($719,375)
• Norfloxacin ($710,766)
• Glibenclamide ($653,162)
• Doxycycline ($548,019)
• Risperidone ($486,959)
• Cefuroxime ($399,884)
• Ofloxacin ($362,786)
• Amoxicillin + sulbactam ($196,700)
• Capreomycin ($192,502)
• Lomefloksatsin ($59,309)

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products for the American and European markets to treat cancers more effectively than current treatments, while costing less, and without the toxicities associated chemotherapies. It is currently working on the DCVax-L personalized immune therapies for solid tumor cancers.

The company announced today that its Phase III clinical trial with DCVax-L for brain cancer has begun at King’s College Hospital in the U.K., a major European center for neuro-oncology. Other sites across Europe, including three more in the U.K. and nearly 20 in Germany, are in varying stages of preparations for the trial.

This particular Phase III trial is for newly diagnosed Glioblastoma multiforme (GBM). This is the most common and lethal form of brain cancer. The trial is well under in the United States with 46 active sites presently. Total enrollment in the U.S. and Europe is expected to reach 312 patients.

Under present treatment methods, brain cancer patients have tumors recur within 7 months and they typically live less than 15 months. Northwest Biotherapeutics’ DCVax-L mobilizes a patient’s entire immune system to attack the full set of biomarker targets on the tumor. In prior Phase I/II trials of DCVax-L, tumors did not recur for two years and patients lived for three years. Additionally, a number of patients lived longer, with two patients exceeding 10 years.

For additional information about Northwest Biotherapeutics, its DCVax-L drug, and the Phase III trial, please visit www.nwbio.com

Let us hear your thoughts below:

Trio Resources, an exploration and small-scale processing company reported financial results for the second quarter ended March 31, 2013, marking the first revenues recorded since the company’s inception in May, 2012. The company also recapped its first-quarter achievements, including its five-year off-take agreement with United Commodity AG.

“During the first quarter, we continued to distinguish ourselves from other junior mining companies by executing on our strategy to monetize our significant stockpiles of mineralized materials and securing a five year off-take agreement with United Commodity AG, one of the world’s leading processors of precious metals,” Duncan Reid, CEO of Trio Resources stated in the press release. “By closing the more than $30 million United Commodity deal, we not only reached a major milestone by generating our first revenues as a public company, but we secured a consistent and significant revenue stream that will enable us to fund operations and future growth opportunities for years to come.”

Trio reported a second-quarter net loss of $489,965, compared to a net loss of $686,801 from the first quarter of 2013. Comprehensive net loss was $464,214, or $0.0014 per basic and diluted share, as compared to a net loss of $699,682, or $0.002 per basic and diluted share, for the first quarter of 2013.

The company achieved revenues of $166,299, the first revenues the company recorded since it was established May 16, 2012.

Operating expenses decreased by 4 percent to $656,264 from operating expenses of $686,801 from the previous quarter of 2013.

“Overall, we are incredibly pleased with the progress we are making and we believe Trio Resources is well-positioned for continued success,” Reid stated. “Going forward, based on our agreement with United Commodity and the strong recovery rates we are seeing with each shipment of our mineralized material, we are confident we will achieve quarterly revenues in the range of $1 to $1.5 million.”

For more information visit www.trioresources.com

Let us hear your thoughts below:

eMagin, a leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how, and mobile display systems, announced yesterday that it has developed the world’s brightest family of super bright, energy efficient, and full color organic light emitting diode (OLED) microdisplays, called the Color OLED-XLS™.

At 1000 nits of luminance, the Color OLED-XLS™ blows away the industry standard for brightness four times over. This new display is fully compatible with eMargin’s entire VGA, SVGA, SXGA, and WUXGA, and only requires half of the power of the company’s current color displays at the same brightness. This breakthrough display technology enables a much broader range of optical solutions for augmented vision/reality products used in simulation and training devices, or any other head-mounted display application. Additionally, this technology is perfectly suited for medical, maintenance, and process-control “see-through” data glasses and safety goggles.

eMagin’s initial showcase of its breakthrough Color OLED-XLS will be at the Vancouver Convention Center next week for the Society for Information Display, booth #1029. Fully qualified production units are scheduled for release by the fourth quarter 2013, and engineering samples are available immediately.

“Our clients have been asking us to push the known limits in order to create more versatile color microdisplays that are both visible in bright environments and power efficient. We have met and surpassed both requirements with the development of the Color OLED-XLS,” said Andrew G. Sculley, president and CEO of eMagin Corporation. “This technology will enable indoor and outdoor augmented reality headsets for commercial, military and industrial use. We are well on the way to OLED microdisplays that can be even brighter for aircraft heads-up displays and consumer data glasses.”

For further information, please visit www.emagin.com

Let us hear your thoughts below:

VistaGen is a biotech company focused on using stem cell technology to generate new, safer variants (drug rescue variants) of once-promising small molecule drug candidates that were developed but ultimately discontinued by large pharmaceutical companies due to heart or liver toxicity issues. VistaGen aims to use their proprietary stem cell technology as a previously unavailable cost effective way to re-examine and ultimately “rescue” such lost drugs, thereby recovering the value from what is usually a substantial prior investment in research and development.

The company recognizes the drug discovery and development crisis facing the U.S. pharmaceutical industry, where increasingly big investments are required for new drug development but not enough new drugs are being finally approved. Using its technology to derive mature human heart and liver cells from pluripotent stem cells, VistaGen continues to develop unique bioassay systems for assessing potential toxicity issues right in the laboratory, providing a way for researchers to successfully modify drug candidates using an economical tweak and test approach.

It’s a development that combines human pluripotent stem cell technology with modern medicinal chemistry to create an important new tool for drug research and development. With human heart cells and liver cells derived from pluripotent stem cells, VistaGen believes that their principal products, CardioSafe 3D™ and LiverSafe 3D™, will allow them to assess the heart toxicity, liver toxicity, and metabolism profile of new drug candidates with greater speed and precision than animal testing and traditional cellular assays currently used in the drug development process.

Although this represents an important new capability that could save the pharmaceutical industry billions of dollars in development costs which might otherwise be lost, VistaGen sees it as a tool that they themselves can use to build a pipeline of resuscitated drug candidates. The company plans to license their drug rescue variants to pharmaceutical companies pursuant to development and marketing arrangements designed to generate optimum revenue. They are also exploring opportunities to advance nonclinical development of potential cell therapy and regenerative medicine pilot programs focused on blood, cartilage, heart, liver, and pancreas cells, based on the proprietary differentiation and production capabilities of their stem cell technology platform.

For additional information, visit www.VistaGen.com

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board

Blue Gold Tailing Technologies is a water remediation company focusing on transforming contaminated waters into pure, safe, drinkable water. The company’s environmentally safe solutions address global water purification, restoration, and contamination issues, adhering to EPA guidelines as to what constitutes safe agricultural or drinkable water. Blue Gold then tailors these guidelines to acceptable standards in the jurisdiction in which the technology is used. This technology can also be used to recover heavy and precious metals from mine tailings.

Privately held Blue Gold is currently undergoing acquisition by Golden Cross Resources via merger with Golden Cross’ Ontario subsidiary. The emerging company will operate as “Blue Gold Water Technologies,” functioning as a waste water remediation and tailings processing business with three proprietary product lines: Pureinator Plants, Process Mine Tailings, and Smartsan.

The company’s low-cost Pureinator Plants produce safe, potable water from any source, including seawater, groundwater, and contaminated or polluted water, in an environmentally friendly manner. Through “build-own-operating” contracts, Blue Gold designs, operates, and maintains a client’s water and wastewater treatment system based on the appropriate technological and economical solution for the client.

Blue Gold’s patent pending Blue Gold LAREMUTEC Technology is short for Laser Aided Methodology with Ultrasonic and Thermo-Electric Conductivity. The technology begins with pond mind tailings or a tailings tank and results in the recovery of precious metals (platinum, gold, silver, uranium) calculated to a 60%-96% level.

SMARTSAN is a green sanitation system designed for rural areas affected by water-stress where basic infrastructure for water/waste-water is not economically viable. Among other features, the product processes raw sewage into usable grey water, is portable and easy to install, operate, and maintain, and doesn’t require connection to a municipal water supply or sewer infrastructure.

Blue Gold in January 2012 commenced its first commercial project in Mexico at a private waste management sanitary landfill site where the company estimates 3.3 million tons of household and industrial waste have collected. As of February 1, 2013, Blue Gold had treated 461 million liters of water at the site, the equivalent of more than 170 Olympic-size swimming pools.

Upon completion of the acquisition by Golden Cross, Blue Gold will maintain its strategy to commercialize or license new water technologies to handle and treat domestic and industrial waste under the guidance of Golden Cross’ new president and CEO David Rowson as successor to the resigning current chief executive, Tom Kennedy.

For more information, visit www.goldencross.ca

Let us hear your thoughts below:

The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker®-brand low frequency audio transducers that provide an immersive entertainment experience for audiences, just announced its results for the first quarter ended March 31, 2013.

The company featured the following financial highlights and recent developments:

• Net loss decreased by 6% for the three months ended March 31, 2013 compared to the three months ended March 31, 2012.
• Total current assets increased 5.9%, or $51,034, to approximately $912,000, as of March 31, 2013 compared to March 31, 2012, attributed primarily to the increase in cash which resulted from the sale of the Company’s stock and warrants in March 2013.
• Net increase in cash and cash equivalents of $123,001, as of March 31, 2013 compared to March 31, 2012, primarily consisting of net cash provided by financing activities of $230,217 partially offset by net cash used in operating activities of $107,216.
• For the three months ended March 31, 2013, revenue totaled $525,427 compared to revenue of $729,137 for the same period a year earlier.
• $250,000 of equity investment received from a new Private Placement investor in the first quarter. An additional $515,000 from previous Private Placement investors received subsequent to the quarter end.
• Expanded footprint in China with the installation of eighth ButtKicker “4D” theater system for Lumière Pavilions in Beijing.
• Entered into a Joint Marketing Agreement with Digital Cinema Destinations Corp. All 300+ stadium seats in one of the largest 3D auditoriums at their Solon Cinema 16 location will be ButtKicker enabled as the initial installation.
• Joined D-Tools Manufacturer Vantage Point (MVP) Program.
• Partnered with Warner Brothers for this Summer’s Release of “Warner Bros. Pictures and Legendary Pictures Pacific Rim” by Oscar® nominee director Guillermo del Toro.
• Widened live in-arena game testing of the ButtKicker Live! broadcast technology with major sports league to include two potential broadcast partners.
• Began in-depth discussions with additional potential sports league for ButtKicker Live!
• Joined Nationwide, the largest buying and marketing organization in North America, with more than 3,500 members operating more than 10,000 store fronts.
• ButtKicker products were a Nationwide “Featured SOLUTION” at their Primetime! Buying Show in Las Vegas.
• Hired industry veteran National Sales Manager to lead domestic home theater sales initiatives.

Mark Luden, President of Guitammer, stated, “We started off 2013 by significantly raising the visibility of our ButtKicker® technology by strategically partnering with established market leaders. This not only raised immediate brand awareness for our products within the entertainment industry, but also positions us for growth moving forward. In addition, we welcomed our new National Sales Manager, Home Theater, to oversee home theater sales of ButtKicker brand products and generate an increase in domestic sales volumes.”

“Furthermore, we increased our footprint of both international and domestic movie theaters, a trend we expect to continue,” added Luden. “We expect to launch direct to consumer sales with one or more of our theater operators by the end of Q3 to help position us for Q4 consumer holiday sales.

“Importantly, we continued to progress with our live in-game testing of the ButtKicker Live! broadcast technology and expanded our efforts to include an additional sports partner to help us begin commercializing this technology, potentially this year.”

Addressing the decrease in Q1 revenues, Luden stated, “The decrease in revenues is primarily attributed to the following factors: the first quarter of 2012 had a sizeable stocking order from an OEM customer and the first quarter of 2013 did not have a stocking order of that magnitude; the first quarter of 2012 had more backorders that had to be fulfilled than the first quarter of 2013; and the economic slowdown in Europe caused certain restocking orders from established distributors to be delayed. However, our net loss decreased by 6%, and our EBITDA loss decreased by approximately $13,845 in the first quarter of 2013, compared to the first quarter of 2012. We do expect to see domestic sales volumes increase throughout the remainder of 2013.”

Richard Conn, Chief Financial Officer of Guitammer, provided the following guidance for the rest of this year: “We believe that our operations, exclusive of any research and development costs, can become operationally cash flow positive on an ongoing basis for our core products business by the end of the fourth quarter of 2013 as we continue securing additional capital,” stated. “With this additional financing, we anticipate the purchase of adequate inventory to meet existing sales demand and to be able to increase sales through increased sales and marketing activities as previously described.”

For more information, visit www.guitammer.com

Let us hear your thoughts: The Guitammer Company, Inc. Message Board

Brekford has been a public safety technology and services solutions partner to public sector agencies at the local, state, and federal level for over ten years. The company’s range of solutions include automated traffic enforcement programs, delinquent municipal receivables processing and collection, turnkey law enforcement vehicle upfitting services, and a suite of mobile computer and video technology products.

The company announced today that it won a three-year contract with the city of Asheville, North Carolina, for the provision of parking citation issuance, processing, and delinquent collections. The contract includes the provision of wireless handheld enforcement devices, web-based parking citation processing software and other processing services, in-state and out-of-state DMV look-ups, notice printing and mailing, real-time public access website, online appeal system, payment processing, and optional delinquent collection services.

Brekford will coordinate closely with Asheville’s Parking and Treasury Services Division, and will also support the enforcement efforts of both the city’s police and fire departments. In addition, the company’s technology will be integrated into the Parking Services Division’s technology platform in order to provide a seamless exchange of data between the parking and payment systems to maximize efficiency and accuracy.

The company’s focus on enforcement and out-of-state collections helped it win the contract. There is a vast marketplace for Brekford to win similar contracts with various municipal governments across the country. It is estimated that $40 billion of uncollected receivables is sitting on the books of municipal governments nationwide.

For further information about Brekford Corp., visit www.brekford.com

Let us hear your thoughts below:

Cardica announced the completion of enrollment for the European clinical study of its MicroCutter XCHANGE 30, which is a cartridge-based cutting/stapling device with a 5-millimeter shaft diameter and a cross-sectional area that is more than six times smaller than the standard 12-millimeter surgical staplers currently in use.

The trial has been created to evaluate the XCHANGE 30’s safety in various gastrointestinal surgical procedures in support of a 510(k) filing for market clearance from the FDA. The company expects to file regulatory documents with the FDA in the third quarter of calendar 2013, based on consistent product performance and positive unaudited clinical outcomes of the trial so far.

“We would like to express our sincere thanks to the investigators and patients for their enthusiasm in participating in the trial to advance the XCHANGE 30, the smallest cutting and stapling device available today,” said Cardica President and CEO Bernard A. Hausen, M.D., Ph.D.

In total, 160 patients have been enrolled at seven centers in Germany for the prospective, single-arm, multicenter, non-inferiority clinical study. The procedure results will be contrasted with historical adverse event reports for comparable procedures performed with currently available stapling devices. Adverse events typically associated with current surgical staplers include staple line leakage, staple line bleeding, staple line strictures, and surgical infections.

A designer and manufacturer of proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures, Cardica possesses a technology portfolio that is intended to minimize operating time and enable minimally invasive and robot-assisted surgeries. The company manufactures and markets its automated anastomosis systems, which include the C-Port Distal Anastomosis Systems and PAS-Port Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and Cardica has shipped more than 45,200 units worldwide.

For more information, visit www.cardica.com

Let us hear your thoughts below:

First Independence Corp. and its subsidiary, The Codesmart™ Group, an ICD-10 education and solutions group, reported that its Codesmart™ University study programs are now eligible for Continuing Education Units (CEU) for existing medical coders, as certified by the Association of Professional Coders (APPC) and the American Health Information Management Association (AHIMA).

ICD-10, or the tenth revision of the International Classification of Diseases, is approved by the World Health Organization for the designation of the aspects of disease treatment that include categories of diseases and treatment modalities for them. This tenth revision of the ICD has been broken down into more than 141,000 designations vs. only 17,000 codes, diagnoses, and procedures in the previous version ICD.

The Codesmart Group says the U.S. Department of Health and Human Services has mandated that all medical practices, hospitals, and other medical record keeping organization be trained and ICD-10 compliant by October 1, 2014. Codesmart University’s eligibility as a CEU provider positions it within the appropriate realm within the coding educational system and government mandate.

“With the two best recognized licensing organizations offering CEU credit, which medical coder members are required to obtain on a yearly basis in order to maintain their certifications, this is an acknowledgement that Codesmart University may be considered the “Gold Standard” of ICD-10 education,” Ira Shapiro, chairman and CEO of the Codesmart Group, stated in the press release. “Our methodology is integrated and flexible and it allows for any kind of adult learner to succeed in learning this information in any of our programs of study whether they are physicians, nurses, medical coders, or a new student looking to embark on a career in medical coding.”

The Codesmart Group also provides solutions for ICD-10 transitions, outsource coding, coding audits, critical documentation improvement, and the revenue cycle continuum.

For more information, visit www.codesmartuniversity.org

Let us hear your thoughts below:

Cinedigm and Universal Studios Home Entertainment have announced a strategic multi-year agreement. Premier home entertainment company, Universal Studios will provide supply-chain services across the United States for Cinedigm’s growing library of digital films and other content. Cinedigm’s existing sales team will continue implementing sales directly to consumers.

Cinedigm’s existing library holds over 5,000 titles of which includes acclaimed independent films, award-winning documentaries from Docurama Films®, next-gen indies from Flatiron Film Company®, as well as festival picks through partnerships with Tribeca Film and the Sundance Institute. Cinedigm also distributes award-winning and Oscar®-nominated films.

Chris McGurk who currently sits as Chairman of the Board and as CEO of Cinedigm commented, “Having worked with Craig Kornblau at both Disney and Universal, I’m thrilled to be working with him and the entire Universal Studios Home Entertainment team again. With Universal by our side, we look forward to rapidly expanding our home entertainment business and are certain that more opportunities to work together will develop as this partnership evolves.”

“Cinedigm is an excellent complement to our evolving portfolio of distribution partners,” stated Craig Kornblau who currently implements the role of President of Universal. “Chris and his team have created an innovative, entrepreneurial and fast-growing company with a substantial film and television library, which, paired with Universal’s formidable home entertainment distribution structure, effectively positions our companies for a long and prosperous collaboration.”

Chief Strategy Officer of Cinedigm, Bob Fiorella, oversaw all negotiations leading to the agreement on Cinedigm’s behalf. It has been over a decade of innovation for Cinedigm, leader of the digital distribution revolution.

To learn more, visit: www.cinedigm.com

Let us hear your thoughts below:

As the $6 billion U.S. market for gluten-free products continues to expand, the Aristocrat Group Corp. announced today that it is working closely with Distilled Resources, Inc. (DRInc) to ensure that its debut vodka brand meets all the necessary requirements to be certified “gluten-free” by the federal government.

“Labeling our product as gluten-free will be a tremendous advantage in standing out in the marketplace,” stated ASCC CEO Robert Federowicz. “Nearly a third of all Americans report that they’re trying to cut back on gluten, and vodka is by far the most popular spirit in the country. By having ‘gluten-free’ on our bottles, consumers will be able to feel 100 percent confident that they’re enjoying their favorite beverage uncontaminated by so much as a hint of gluten.”

It has been estimated that the market for gluten-free products is even larger than the booming $5.5 billion vodka market. By producing a branded, gluten-free vodka, ASCC plans to capitalize on both markets’ growth.

ASCC will need to get approval from the Alcohol and Tobacco Tax and Trade Bureau (TTB) before adding “gluten-free” to the label of its new vodka brand. For years, this agency’s strict liquor labeling laws prevented manufacturers from labeling any spirits as gluten-free. That changed last year, when TTB began allowing companies to advertise distilled spirits as gluten-free if they were made from gluten-free ingredients.

Distilled in the U.S. from Idaho russet potatoes, ASCC’s new vodka could soon be one of only a small handful of spirits to bear “gluten-free” labeling.

For more information on the Aristocrat Group, visit www.aristocratgroupcorp.com

Let us hear your thoughts: The Aristocrat Group Corp. Message Board

ISCO had a solid day on Tuesday and is now pushing on a three-month trendline as the pps climbed back over the 50-day and 200-day moving averages. Technical traders will be looking for the upward momentum to continue as the chart tries to hold the new higher low and build a long-term uptrend.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

Let us hear your thoughts below: